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Several studies have investigated the differences in tumour charac-
teristics between breast cancer in BRCA1-carriers and other
patients, aiming to obtain insight into features that might be of
importance for recognizing patients with BRCA1-related tumours.
In many studies, it was observed that BRCA1-associated breast
cancers are more frequently histologic grade 3 (Eisinger et al,
1996; Marcus et al, 1996; Johannsson et al, 1997; Karp et al, 1997;
Lakhani et al, 1997; Armes et al, 1998; Lynch et al, 1998) and that
they express receptors for oestrogen and progesterone less
frequently (Johannsson et al, 1997; Karp et al, 1997; Lynch et al,
1998;  Loman et al, 1998 Verhoog et al, 1998; Armes et al, 1999).
Both features are usually associated with a poorer prognosis. 
However, all studies were performed on highly selected groups
of patients, which might lead to survival bias and underestimation
of the differences under study. The majority of studies examined
tumours from families with a high incidence of breast cancer
(Eisinger et al, 1996; Marcus et al, 1996;  Johannsson et al, 1997;
Lakhani et al, 1997; Loman et al, 1998; Lynch et al, 1998;Verhoog
et al, 1998), from patients with an early onset breast cancer (Armes
et al, 1998, 1999), or from specific populations with founder muta-
tions (Karp et al, 1997). Moreover, in most studies in which the
cases were selected from breast cancer families, the controls were
breast cancer patients without a positive family history but no defi-
nite proof of a negative BRCA1 mutations status (Eisinger et al,
1996; Verhoog et al, 1998) or an unknown family history (Marcus
et al, 1996; Johannsson et al, 1997; Lakhani et al, 1997). This
might also give an underestimation of the differences under study. 
Recently, we completed a BRCA1 mutation screening study on a
hospital-based cohort of 642 breast cancer patients not selected for
family history or age at diagnosis. BRCA1-germline mutations
were identified in 10 patients by using a mutation-scanning assay
that would detect approximately 70% of the currently known
Dutch mutation spectrum (Papelard et al, 2000). The aim of this
analysis is to investigate the clinical and pathological features of
these BRCA1 associated carcinomas as compared to other breast
cancers in a representative sample. 
METHODS 
Patients and Setting 
Population 
From January 1984 until November 1996 all primary invasive
breast cancer patients surgically treated at the Leiden University
Medical Centre (LUMC) regardless of age or family history have
been asked to provide a blood sample for research purposes.
Mutation screening of BRCA1 was performed anonymously using
an assay targeted at known founder mutations in the Dutch popula-
tion. In brief, 15 PCR-amplifiers covered gene regions known to
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products were size-fractionated on an ABI377™ DNA sequencer,
and those showing additional bands were re-amplified and
sequenced. In addition, two PCR-amplifiers specifically detected
the junction of the two major large genomic deletions when present
(Petrij-Bosch et al, 1997). Based on the currently known mutation
incidence among Dutch breast cancer families (http://www.medfac.
leidenuniv.nl/lab-devilee/Lab/b1nlmuts.htm), this assay would
detect ~70% of that incidence. The Committee of Medical Ethics of
the LUMC approved the study protocol. A more detailed descrip-
tion of this population and the BRCA1 mutation testing is given in
Papelard et al, 2000. 
Patients 
For the current analysis, tumours of patients with BRCA1 associ-
ated carcinomas were compared to tumours of patients where no
BRCA1 mutation was detected. For each patients with BRCA1
associated carcinomas five controls were selected, matched by age
at diagnosis of the first breast cancer. 
Measurements 
Clinical characteristics 
Data on age, tumour size, axillary nodal status, and preoperative
therapy were collected from the medical records. Tumour size was
extracted from the local pathology report. 
Histological typing 
Histological typing was done according to the WHO classification
of 1981. The invasive cancer was graded 1, 2 or 3 with the Bloom-
Richardson system modified by Elston and Ellis (Elston et al,
1991). Other features assessed were type and amount of in situ
carcinoma around the invasive lesion and lymphangio invasion. 
Immunohistochemical typing 
The immunohistochemical assays were performed in one refer-
ence laboratory, using 4-µ m tissue sections. Staining with each
monoclonal antibody was performed in one session for the whole
series. Anti-oestrogen receptor (ER) antibody (1D5, DAKO) was
diluted 1:100, anti-progesterone receptor (PR) antibody (A 0098,
DAKO) diluted 1:200, anti-HER2/neu antibody (3B5) (Van de
Vijver, 1988) diluted 1:20 000, anti-p53 antibody (DO-7, DAKO)
diluted 1:500, anticyclin D1 antibody (DCS-6, Neomarkers)
diluted 1:500 and anti-E-cadherin antibody (C 20820,
Transduction laboratories) diluted 1:8000. Before incubation,
antigen retrieval was performed in 10 mmol/L citrate buffer for all
antibodies, except the anti HER2/neu antibody (Cattoretti et al,
1993). Biotinylated rabbit-antimouse immunoglobulin and a
preformed complex of biotinylated horseradish peroxidase and
streptavidin (SABC) was used for the detection of the bound
primary antibody except for detection of the progesterone receptor
where biotinylated swine-antirabbit immunoglobulin was used
before SABC. 
The scoring of the stained sections was done by using a semi-
quantitative system based on the mean staining intensity and an
estimation of the percentage of positive tumour cell nuclei (p53,
cyclin D1, oestrogen and progesterone receptor) or percentage
of cells with membrane staining of the tumour (HER2/neu, E-
Cadherin). The mean staining intensity could vary from 0 (none),
1 (weak), 2 (moderate) to 3 (strong). The percentages of positive
nuclei or membranes were categorized as 0 (0%), 1 (1% to 10%), 2
(11% to 25%), 3 (26% to 50%), 4 (51% to 75%) or 5 (76% to
100%). The staining score was calculated as the sum of mean
staining intensity and percentage of positive tumour cells (range 0
to 8). p53 and cyclin D1 were analysed by using a staining score of
0 to 4 (called negative) and 5 or more (called positive). Expression
of oestrogen and progesterone receptor, E-Cadherin and
HER2/neu were analysed as any positive staining versus none. The
cut-off levels used for scoring the immunohistochemical analyses
of cyclin D1 and p53 were based on good correlation between
immunohistochemistry and the presence of genetic alterations
(cyclin D1, p53, E-cadherin and HER2/neu). 
Procedure and availability of material 
All outcomes were assessed by the same observer: the clinical char-
acteristics were assessed by HP; the histopathologic and molecular
phenotypes were assessed by HP and MJ v d V. All data were gath-
ered blinded for mutation status. Histological tissue was available
of all 10 cases and 47 out of 50 control tumours. Regarding the
patients receiving preoperative chemotherapy, all immunohisto-
chemical-staining results were based on biopsies taken before the
patients received this preoperative chemotherapy. Two of these
patients showed a complete remission of their tumour.
Consequently, for these patients tumour size was preoperatively
radiological assessed, at the time of diagnosis, before neoadjuvant
chemotherapy treatment, and DCIS, LCIS and lymphangio inva-
sion could not be assessed. The radiological tumour size assess-
ments were not included in the calculation of the mean tumour size. 
Statistical methods 
Clinical and tumour characteristics were compared by using χ 2 test
or Fisher’s exact test when any of the expected frequencies were
less than five. We considered differences related to two-sided 
P-values less than .05 to be statistically significant. All analyses
were performed using SPSS-PC version 9.0. 
RESULTS 
Due to matching, the mean age at diagnosis of the 10 patients with
BRCA1 associated carcinomas and the 50 patients without BRCA1
associated carcinomas was the same: 40.2 years (95% CI: 
36.5 – 43.9 and 38.4 – 42.0, respectively), ranging from 30 to 48.
Patients with BRCA1 associated carcinomas tended to have larger
tumours and more often positive nodes (Table 1). Furthermore, the
BRCA1 associated tumours tended to have a higher histologic
grade, a less lower prevalence of in situ carcinoma, a lower
frequency of high expression of cyclin D1 and a higher frequency
of elevated p53 protein than the controls. None of these differ-
ences was statistically significant (Tables 2 and 3). Three patients
received preoperative chemotherapy as part of a clinical trial (4
courses of 5-fluorouracil (600 mg/m2), epirubicine (60 mg/m2) and
cyclophosphamide (600 mg/m2)). BRCA1 associated tumours
were more often oestrogen and progesterone receptor negative
(respectively P = 0.001 and P = 0.002) (Table 3). No differences in
the expression of HER2/neu and E-cadherin were observed
between the two groups. 
DISCUSSION 
The aim of this analysis was to study whether tumours of patients
with  BRCA1 associated breast carcinomas are different from
1348 GH de Bock et al
British Journal of Cancer (2001) 85(9), 1347–1350 © 2001 Cancer Research Campaigntumours of patients without BRCA1 associated breast carcinomas
in a hospital-based cohort not selected for family history or age at
diagnosis. In BRCA1 associated tumours receptors for oestrogen
and progesterone were expressed less frequently than in controls.
The finding regarding oestrogen and progesterone expression is in
line with previous publications (Johannsson et al, 1997; Karp et al,
1997; Loman et al, 1998; Lynch et al, 1998; Verhoog et al, 1998;
Armes et al, 1999). Absence of oestrogen and progesterone
receptor expression has been even suggested as a potential indi-
cator for the presence of a BRCA1 germline mutation (Brown et al,
1999; Eisinger et al, 1999). In our study, the mutation carriers
received preoperative chemotherapy more often (P = 0.004) than
the patients in the control group. We consider this a chance
difference because at the moment of treatment, a patient’s BRCA1
status was unknown. 
The trend towards a higher proportion of positives nodes among
mutation carriers is supported by the study of Karp (Karp et al,
1997), whereas other groups did not find a difference (Armes et al,
1998; Verhoog et al, 1998), or reported a lower percentage of
lymph node-positive cases among mutation carriers (Johannsson
et al, 1997). The trend towards larger tumours among the mutation
carriers was not reported by others (Johannsson et al, 1997; Armes
et al, 1998; Loman et al, 1998; Verhoog et al, 1998). Some studies
have reported that BRCA1-related breast tumours are more
frequently of a medullary or atypical medullary type (Karp et al,
1997; Johannsson et al, 1997; Marcus et al, 1996; Armes et al,
1998; Lakhani et al, 1998), which we could not confirm. We did
not find any differences regarding tumour type. In line with other
studies (Eisinger et al, 1996; Marcus et al, 1996; Johannsson et al,
1997; Karp et al, 1997; Lakhani et al, 1997; Armes et al, 1998;
Lynch et al, 1998), among the BRCA1-mutation carriers, a higher
proportion of high-grade tumours with a higher mitotic rate, tubule
formation and nuclear grade was observed. In a recent study in
which differences between sporadic breast cancers and cancer
involving BRCA1 mutations were studied by means of a multi-
factorial model, a higher mitotic count has been identified as a key
feature of the histologic phenotype of breast cancers in BRCA1
mutations carriers (Lakhani et al, 1998). Also, in accordance with
other studies (Lakhani et al, 1997; Armes et al, 1998), the BRCA1-
related tumours were associated with a lower frequency of in situ
carcinoma. The trend towards higher incidence of lymphangio
invasion was not found by others (Armes et al, 1998; Robson et al,
1998). Armes et al, reported a significantly lower proportion of
tumours showing cyclin D1 over-expression among BRCA1-
related tumours (Armes et al, 1999). Our results showed the same
differences, but did not reach statistical significance. The trend
towards a higher proportion of p53-positive tumours among
BRCA1 carriers is in agreement with the results from several other
studies which all reported statistically significant differences
between mutation carriers and non-mutation carriers (Crook et al,
1997; Lynch et al, 1998; Armes et al, 1999; Philips et al, 1999).
HER2/neu expression was infrequent and did not differ between
the BRCA1-related tumours and the controls, which is in line with
previous findings (Lynch et al, 1998). In accordance with previous
publications concerning E-cadherin expression in BRCA1 carriers
(Robson et al, 1998; Armes et al, 1999; Jacquemier et al, 1999),
we did not observe different expression levels. 
As far as we know, this is the first study in which clinical and
pathological features of BRCA1 associated carcinomas are studied
in a hospital-based cohort of breast cancer patients not selected
for family history or age at diagnosis. The small number of
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Table 1 Clinical characteristics in relation to mutation status 
BRCA1 positive BRCA1 negative P
No. (%) No. (%) 
Tumour size (cm) 
– ≤ 2 3/10 (30) 21/47 (45) 0.49 
– > 2 7/10 (70) 26/47 (55) 
– unknown 0 3 
– mean (SE) 3.9 (0.91) 3.1 (0.31) 
– range 1.0 to 9.5 0.5 to 10.0 
Axillary nodal status 
– negative 3/9 (33) 29/50 (58) 0.28 
– positive 6/9 (67) 21/50 (42) 
– unknown 1 0 
Preoperative chemotherapy 
– yes 3/10 (30) 0/50 (0) 0.004 
– no 7/10 (70) 50/50 (100) 
Table 2 Histologic tumour characteristics in relation to mutation status 
BRCA1 positive BRCA1 negative P
No. (%) No. (%) 
Tumour type 
– ductal carcinoma 8/10 (80) 39/47 (83) 0.92 
– lobular carcinoma 1/10 (10) 5/47 (11) 
– other 1/10 (10) 3/47 (6) 
Histologic grade 
– 1 0/10 (0) 5/47 (11) 0.24 
– 2 4/10 (40) 26/47 (55) 
– 3 6/10 (60) 16/47 (34) 
Mitotic rate 
– 1 (0–6) 4/10 (40) 26/47 (55) 0.66 
– 2 (7–13) 2/10 (20) 8/47 (17) 
– 3 (>13) 4/10 (40) 13/47 (28) 
Tubule formation 
– 1 (> 75%) 0/10 (0) 5/47 (11) 0.29 
– 2 (5–75%) 1/10 (10) 11/47 (23) 
– 3 (< 5%) 9/10 (90) 31/47 (66) 
Nuclear grade 
– I 0/10 (0) 0/47 (0) 0.29 
– II 2/10 (20) 20/47 (43) 
– III 8/10 (80) 27/47 (57) 
DCIS# 
– absent 6/8 (75) 24/47 (51) 0.27 
– present 2/8 (25) 23/47 (49) 
LCIS# 
– absent 8/8 (100) 41/47 (87) 0.58 
– present 0/8 (0) 6/47 (13) 
Lymphangio invasion# 
– absent 4/8 (50) 37/47 (79) 0.18 
– present 4/8 (50) 10/47 (21)
Table 3 Proportion of cases expressing immunohistochemical markers 
Positive for BRCA1 positive BRCA1 negative P
No. (%) No. (%) 
Oestrogen receptor 2/10 (20) 32/41 (78) 0.001 
Progesterone receptor 2/10 (20) 31/41 (76) 0.002 
Cyclin D1 1/10 (10) 15/43 (35) 0.25 
p53 6/10 (60) 11/42 (26) 0.06 
HER2/neu 1/10 (10) 4/40 (10) 1.0 
E-cadherin 8/9 (89) 34/40 (85) 1.0 BRCA1 mutation carriers in our cohort inherently limits the statis-
tical power of the study so that for some variables only trends
could be observed. Since the mutation analysis only would detect
70% of the mutations in the population, there may be an under-
estimation of the differences detected in the study. We conclude
that the features of BRCA1 associated tumours detected in a
hospital-based series of breast cancer patients not selected for
family history or age at diagnosis are similar to those tumours that
were selected on these criteria. The opinion of the Breast Cancer
Linkage Consortium that inclusion of breast-cancer histology
may be part of the design of genetic testing policy (Lakhani et al,
1997; Lidereau et al, 2000) also seems to hold in a general 
population. 
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